Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease

INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn’s disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much le...

Descripción completa

Detalles Bibliográficos
Autores principales: Szymanska, Edyta, Dadalski, Maciej, Grajkowska, Wieslawa, Szymanska, Sylwia, Pronicki, Maciej, Kierkus, Jaroslaw
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360663/
https://www.ncbi.nlm.nih.gov/pubmed/28337236
http://dx.doi.org/10.5114/pg.2016.64746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360663/
https://www.ncbi.nlm.nih.gov/pubmed/28337236
http://dx.doi.org/10.5114/pg.2016.64746

Ejemplares similares